Understanding GLP-1 medications used for weight loss

How this hub is different from Beema's program pages

Beema's commercial pages explain the live telehealth program, pricing, and how to start an online visit. This hub is the educational layer: how glucagon-like peptide-1 (GLP-1) medicines work, what trials measured, and which questions are clinical rather than something a webpage can answer.

If you already know you want to see whether treatment could be appropriate, the program overview, compounded semaglutide page, and compounded tirzepatide page are the right next clicks. Stay here when you want background first.

How GLP-1 medicines affect appetite and weight

GLP-1 receptor agonists mimic a gut hormone that helps regulate insulin release, slow stomach emptying, and reduce appetite for many people. Dual agonists that also act on glucose-dependent insulinotropic polypeptide (GIP) receptors, such as tirzepatide, add a second incretin pathway. Those mechanisms are why labelled products are used for type 2 diabetes, chronic weight management, or both, depending on the specific approval.

Trial averages are not a personal forecast. STEP-1 reported mean weight change with semaglutide 2.4 mg plus lifestyle intervention versus placebo plus lifestyle intervention. SURMOUNT-1 reported mean weight change with tirzepatide versus placebo. Individual results vary, people leave trials, and regain after stopping is well documented. No ethical clinic can guarantee how much weight a specific person will lose.

What "online GLP-1" care actually means

Yes, you can get GLP-1 care online in the United States. A legitimate program is telehealth: you complete a medical intake, a licensed provider reviews it, and a licensed pharmacy dispenses only if that provider says yes. Beema does that in all 50 states, for compounded semaglutide and compounded tirzepatide when they are legally available and clinically appropriate. Completing intake does not guarantee a prescription. You cannot lawfully add a GLP-1 to a cart like a vitamin, and Beema does not sell research peptides. Beema does not serve patients outside the United States.

Beema's intake is hosted with our clinical partner. Geographic availability, compounding rules, and formulary options still depend on state law and clinical judgment. Cash-pay pricing is disclosed on the compounded semaglutide and compounded tirzepatide pages. This site does not collect insurance information or promise that a plan will cover treatment.

Semaglutide and tirzepatide, in educational terms

Semaglutide is the active ingredient in more than one FDA-approved branded product, used at different doses and for different labelled indications. Tirzepatide is the active ingredient in other FDA-approved branded products. This hub will not treat those brand names as Beema products. Beema does not sell Wegovy, Zepbound, Ozempic, or Mounjaro.

When a Beema provider prescribes, the live options are compounded semaglutide and compounded tirzepatide, only when legally available and clinically appropriate. Compounded medications are not FDA-approved and are not the same as those branded products. Lower price does not, by itself, establish medical necessity or therapeutic equivalence.

Safety facts this library will not skip

Common effects in trials include nausea, vomiting, diarrhea, constipation, and abdominal discomfort, especially while the dose is increasing. Labelled products carry a boxed warning about thyroid C-cell tumors based on rodent data, and they are contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Pancreatitis, gallbladder problems, and other serious risks appear in labelling. Read the safety page and talk with a clinician about your own history.

Pregnancy, planned pregnancy, and breastfeeding change the risk-benefit picture. So do planned surgeries that require an empty stomach, because delayed gastric emptying can matter for anesthesia. Do not start, stop, or restack medicines based on a blog post.

Live Beema program pages

These commercial pages are where pricing, intake, and the compounded offering live. They use different headlines on purpose so this educational hub does not compete with them.

Topic clusters

Cluster headings stay visible even before every child article is published. Links appear only when that article exists in the library.

Longer guides already on Learn

Articles in this hub

• Acne During GLP-1 Treatment: Skin Changes to DiscussWhat is known about acne during GLP-1 weight-loss treatment, including labeled skin reactions, hormone shifts, and when a rash needs urgent medical care.
• Ashwagandha and Weight Loss: Stress Herb, Thin Fat-Loss DataAshwagandha is studied more for stress and sleep than obesity. Evidence limits, thyroid and sedative cautions, and why it does not replace GLP-1 care.
• Berberine and Semaglutide: Supplement vs PrescriptionBerberine is not a GLP-1. It affects metabolic pathways in small trials, can interact with drugs, and should not be stacked blindly with semaglutide.
• Best GLP-1 for Weight Loss: How Clinicians Compare OptionsThere is no universal best GLP-1. Compare trial means for semaglutide, tirzepatide, liraglutide, and pipeline drugs without crowning a winner.
• Bloating on GLP-1 Treatment: Delayed Emptying to WatchWhy GLP-1 medicines can cause bloating and distension, how trial rates compare with placebo, delayed emptying, and which swollen-abdomen patterns need care.
• Body Aches During GLP-1 Treatment: What They Can MeanHow body aches on GLP-1 treatment can relate to a calorie deficit or lean-mass change, and which pain patterns are labeled emergencies such as pancreatitis.
• CagriSema: Semaglutide Plus Amylin, Still InvestigationalCagriSema pairs semaglutide with cagrilintide. See REDEFINE-1 results, the 2026 FDA review window, and why Beema Health does not offer it today.
• Eating on a GLP-1: Practical Diet PatternsHow FDA labels pair GLP-1 medicines with a reduced-calorie diet, plus protein, meal size, and nausea-aware eating tips. Educational, not a meal plan.
• Exercise on a GLP-1: Why Strength Training Still MattersGLP-1 labels include increased physical activity. Why resistance training helps protect muscle during weight loss, and how to start if you feel nauseated.
• Fatigue on GLP-1 Medications: Causes and When to CallWhy fatigue appears in GLP-1 labels, how often trials reported it versus placebo, overlapping causes such as low intake, and when to see a clinician soon.
• Foods That Often Worsen Tirzepatide Nausea (Not a Ban List)Tirzepatide slows gastric emptying, so greasy, oversized, and very sugary meals often worsen nausea. Label-based GI warnings and practical swaps.
• Get GLP-1 Online: Licensed Telehealth in All 50 StatesYes. You can start online in all 50 US states. If prescribed, it is compounded medication, not FDA-approved. Prescription not guaranteed.
• GLP-1 Age Limits: What the FDA Labels Actually SayWegovy injection is labeled for some adolescents 12 and older. Zepbound, Mounjaro, and Ozempic are adult products. Age limit is not one number.
• GLP-1 Constipation: Slowed Digestion and Red FlagsWhy GLP-1 medicines can cause constipation, how often labels report it versus placebo, and warning signs that need prompt medical evaluation right away.
• GLP-1 Cost: Cash-Pay Telehealth Pricing, Explained HonestlyCash-pay telehealth GLP-1 programs charge a bundled monthly rate. See what Beema bills for compounded semaglutide and tirzepatide, with no insurance math.
• GLP-1 Dizziness: Lightheadedness, Fluids, and CareWhy dizziness appears in GLP-1 labels, how dehydration and blood pressure can contribute, hypoglycemia risks, and when lightheadedness needs urgent care.
• GLP-1 Dosing Guide: Titration Schedules and MaintenanceGLP-1 dosing starts low and steps up to limit nausea. Compare labeled weekly and daily schedules, missed-dose rules, and why you should not self-titrate.
• GLP-1 Drugs for Weight Loss: How Treatment WorksGLP-1 receptor agonists reduce appetite and slow gastric emptying. Labeled uses, trial-scale results, safety, and how telehealth prescribing works.
• GLP-1 Injection Site Reactions: Care and Red FlagsHow often Wegovy and Zepbound trials reported injection-site reactions, why antibody status can matter, rotation technique, and which findings need urgent care.
• GLP-1 Maintenance Dose: Staying on Treatment Long TermA GLP-1 maintenance dose is the labeled long-term strength after titration. See Wegovy and Zepbound options, STEP 4, SURMOUNT-4, and why stopping is a plan.
• GLP-1 Medications and Periods: Fertility and CyclesHow GLP-1 weight-loss treatment can change periods, tirzepatide oral-contraceptive cautions, pregnancy warnings, and when bleeding changes need a clinician.
• GLP-1 Medicines While Breastfeeding: What FDA Labels SayWegovy tablets are not recommended while breastfeeding. Injection labels often lack human-milk data and tell clinicians to weigh benefits and risks.
• GLP-1 Microdosing: Meaning, Evidence Limits, and RisksGLP-1 microdosing is an informal trend, not a labeled protocol. How it differs from starter doses, and why splitting pens is risky.
• GLP-1 Near Me: Licensed Telehealth in Every US StateYes. Beema has no clinic to visit. Licensed providers treat adults in every US state by telehealth. Labs still happen locally. Prescription not guaranteed.
• GLP-1 Side Effects: Common Risks Versus Serious SignsCited overview of GLP-1 side effects in weight-loss treatment: nausea, constipation, fatigue, hair loss, labeled warnings, and when to seek urgent care.
• GLP-1 Telehealth for Adults Living in TexasTexas adults can use telehealth GLP-1 care when a licensed clinician reviews them. Chapter 111 telemedicine, rural access, and Beema's 50-state model.
• GLP-1 Telehealth for Houston-Area AdultsHouston adults can use telehealth GLP-1 visits instead of driving to a clinic. Who online care fits, and how Beema's nationwide model covers Houston.
• GLP-1s After Pregnancy: Timing, Feeding, Label WarningsWeight loss is not recommended during pregnancy. After delivery, GLP-1 timing depends on feeding, recovery, contraception, and the product label.
• GLP-1s and Alcohol: Nausea, Calories, Pancreatitis RiskAlcohol is not a universal GLP-1 contraindication, but it can worsen nausea, add calories, dehydrate you, and is a pancreatitis risk factor.
• GLP-1s and Antidepressants: Absorption and Label UpdatesGLP-1s can delay absorption of oral medicines. FDA has evaluated suicidality reports and some labels changed. Never stop an antidepressant alone.
• GLP-1s and Thyroid: Boxed MTC Warning vs HypothyroidismGLP-1 labels carry a boxed warning about rodent thyroid C-cell tumors and contraindicate MTC and MEN 2. That is not the same as Hashimoto's.
• GLP-1s Before Surgery: Aspiration Risk and Dose HoldsGLP-1 labels warn about delayed gastric emptying and aspiration under anesthesia. Only your surgical team should plan a pause before a procedure.
• GLP-1s for Older Adults: Label Data, Muscle, FallsLabels report no overall effectiveness gap at 65 and older, with extra caution at 75+, for dehydration, muscle loss, other medicines, and surgery.
• Hair Loss During GLP-1 Weight Loss: Causes and CareWhat Wegovy and Zepbound labels report about hair loss, how shedding relates to weight reduction, telogen effluvium, and when to see a clinician soon.
• Mazdutide: China-Approved, Not FDA-ClearedMazdutide is a GLP-1/glucagon dual agonist approved in China, not by the FDA. Why U.S. patients cannot treat it as available care today.
• Metformin for Weight Loss: Diabetes Drug, Modest EffectMetformin is FDA-approved for type 2 diabetes, not as an obesity GLP-1. Diabetes Prevention Program data, off-label limits, and what Beema offers.
• Mounjaro Explained: Diabetes Indication and DosingMounjaro is FDA-approved weekly tirzepatide for type 2 diabetes, not a weight-loss indication. Learn labeled doses, SURPASS context, and safety warnings.
• Natural Appetite Suppressants: Evidence and LimitsProtein, fiber, sleep, and volume eating can reduce hunger. Supplements rarely match GLP-1 trial results, and do not replace prescription care.
• Nausea on GLP-1 Treatment: Why It Happens and How to CopeWhy nausea is the most common GLP-1 side effect, how trial rates compare with placebo, and which symptoms mean it is time to call a clinician promptly.
• Not Losing Weight on Semaglutide: Reasons to ReviewWhy some people lose little weight on semaglutide, what STEP responder rates show, titration gaps, and when a clinician should reassess the plan next.
• Not Losing Weight on Tirzepatide: Reasons to ReviewWhy tirzepatide weight change varies, what SURMOUNT-1 data show, how titration and GI limits affect results, and when a clinician should reassess care.
• Orforglipron Oral GLP-1: Data and Access LimitsOrforglipron is a once-daily oral small-molecule GLP-1 from Lilly. Review ATTAIN-1 data, the 2026 Foundayo FDA approval, and why Beema does not offer it.
• Orforglipron vs Semaglutide: Pill Versus Weekly InjectionCompare oral orforglipron (Foundayo) with injectable semaglutide using ATTAIN-1 and STEP 1. Beema Health does not offer orforglipron.
• Rebound Weight Gain After GLP-1: What Trials ShowWeight often rises after GLP-1 medicines stop. STEP 1 extension, STEP 4, and SURMOUNT-4 explain the pattern, and what follow-up can include.
• Retatrutide vs Ozempic: Obesity Trial Drug vs Diabetes BrandOzempic is branded semaglutide for type 2 diabetes. Retatrutide is an investigational triple agonist. Compare mechanisms and trial stages.
• Retatrutide vs Semaglutide: Trial Context, Not a WinnerCompare retatrutide's investigational triple-agonist data with published semaglutide obesity trials. Retatrutide is not a Beema offering today.
• Retatrutide: Investigational Triple-Agonist GuideRetatrutide is an investigational GIP, GLP-1, and glucagon agonist. Review 2026 trial status, safety signals, and why it is not a Beema Health offering today.
• Semaglutide Access for Adults Who Live in TexasTexas residents can pursue semaglutide through licensed telehealth under Chapter 111. What Beema offers, and why research vials are not care.
• Semaglutide for Weight Loss: What Trials and Labels ShowSemaglutide 2.4 mg produced about 14.9% mean weight change in STEP 1. Dose differences from diabetes brands, safety, and compounded care.
• Semaglutide in Houston: Telehealth Access for AdultsHouston adults can be evaluated for semaglutide by a licensed clinician online under Texas telemedicine rules. What the visit covers and what it cannot promise.
• Sermorelin: Discontinued Pediatric GHRH Analog, Not a GLP-1Sermorelin was Geref, a GHRH analog for pediatric growth-hormone testing. It was discontinued, is not a GLP-1, and Beema does not offer it.
• Still Hungry on GLP-1 Treatment: Appetite, Dose, DietWhy appetite can persist on GLP-1 treatment, how titration changes fullness, diet factors clinicians review, and when hunger needs a medical visit soon.
• Stopping a GLP-1 Medicine: Evidence After DiscontinuationStopping a GLP-1 often leads to weight regain in trials (STEP 4, STEP 1 extension, SURMOUNT-4). Why that happens, safety, and how to plan.
• Stopping Mounjaro: What Discontinuation Means for DiabetesStopping Mounjaro can worsen blood sugar and is not a weight-only holiday. Monitoring, SURPASS context, and when to call a clinician.
• Stopping Tirzepatide: Weight, Safety, and Follow-UpStopping tirzepatide (Zepbound or Mounjaro) is associated with weight regain in SURMOUNT-4. Diabetes cautions and how to plan with a clinician.
• Sweating and Weight Loss: Why Detox Myths Fall ShortSweating does not detox you and does not equal fat loss. Why the scale drops after a sauna, and when extra sweat is a safety issue.
• Switching From Wegovy to Zepbound: Labeled Facts GuideThere is no FDA milligram conversion from Wegovy to Zepbound. See SURMOUNT-5 averages, GI overlap, OSA and heart indications, and how clinicians time a switch.
• Switching From Zepbound to Wegovy: Labeled Facts GuideThere is no FDA milligram conversion from Zepbound to Wegovy. See SURMOUNT-5 context, why people switch, timing, GI overlap, and what to tell a clinician.
• Switching GLP-1 Medications: What Clinicians WeighSwitching GLP-1 medicines is a new prescription. There is no official milligram swap. See why people switch, SURMOUNT-5 context, washout, and safety steps.
• Tesamorelin: HIV Lipodystrophy Drug, Not a GLP-1Tesamorelin (Egrifta) is FDA-approved to reduce excess abdominal fat in HIV-associated lipodystrophy. It is not a GLP-1 or a weight-loss drug.
• Tirzepatide in Houston: Telehealth Without a ClinicYes. Houston adults can start tirzepatide care online. Beema has no clinic. If prescribed, compounded tirzepatide may ship. Prescription not guaranteed.
• Tirzepatide in Texas: Telehealth Access and RulesTexas adults can be evaluated for tirzepatide online under Chapter 111 telemedicine rules. Dual-agonist basics and what a provider checks first.
• Tirzepatide Online: Telehealth in All 50 US StatesYes. Beema can evaluate you online in all 50 US states. If prescribed, it is compounded tirzepatide when legally available. Prescription not guaranteed.
• Traveling With a GLP-1: Storage, Pens, Time ZonesA label-based guide to traveling with weekly GLP-1 injections: refrigeration windows, carry-on packing, TSA screening, heat, and time-zone dosing.
• Traveling With Wegovy: Pen Storage and 28-Day WindowWegovy travel guide from the U.S. prescribing information: refrigerator range, 28-day room-temperature window, TSA carry-on tips, and weekly timing.
• Traveling With Zepbound: 21-Day Room-Temp LimitTravel with Zepbound using the FDA label: refrigerate unused pens, 21-day room-temperature limit, no freezing, original carton, and TSA carry-on tips.
• Urinary Changes on GLP-1s: Hydration and Kidney RiskWhy urination can change on GLP-1 treatment, how labels warn about kidney injury from fluid loss, kidney-stone signals, and when low urine output is urgent.
• Water Intake on a GLP-1: Dehydration Risk and FluidsGLP-1 labels warn that vomiting and diarrhea can cause dehydration and kidney injury. What that means for fluids, and why chugging gallons is not a plan.
• Wegovy and Breastfeeding: Tablets vs InjectionWegovy tablets: breastfeeding not recommended. Wegovy injection: no human-milk data, so clinicians weigh benefits and risks. Not medical advice.
• Wegovy Low Doses: Starter Strengths and TitrationWegovy low doses (0.25 and 0.5 mg) are labeled starter steps, not long-term targets. When 1.7 mg is maintenance, and how that differs from microdosing.
• Wegovy Pill: Oral Semaglutide for Weight ManagementThe Wegovy pill is FDA-approved once-daily oral semaglutide for adult weight management and certain heart-risk uses. See fasting rules, titration, and OASIS 4.
• Wegovy Weekly Dosing Chart: Titration and MaintenanceWegovy injection starts at 0.25 mg weekly and usually maintains at 2.4 mg. See the labeled chart, 1.7 mg option, tablets, missed doses, and safety holds.
• Weight-Loss Plateau on a GLP-1: Why Progress SlowsWhy weight loss often slows on GLP-1 treatment, what SURMOUNT analyses show about time to plateau, false stalls, and when to talk with a clinician next.
• What a GLP-1 Doctor Reviews Before PrescribingA GLP-1 doctor is a licensed clinician, not a checkout bot. See history checks, contraindications, follow-up, and how the decision gets made.
• What a GLP-1 Weight-Loss Program IncludesA GLP-1 program is follow-up, titration, supplies, and clinical judgment, not a one-time vial. How telehealth works and what Beema's model includes.
• What Is Ozempic? Diabetes Indication, Dosing, RisksOzempic is an FDA-approved weekly semaglutide injection for type 2 diabetes, heart, and kidney risk - not a weight-loss indication. Prescription required.
• What Is Saxenda? Daily Liraglutide for Weight LossSaxenda is FDA-approved daily liraglutide 3 mg for chronic weight management. See how it differs from weekly GLP-1 shots, SCALE data, dosing, and risks.
• What Is Wegovy? Weight-Loss Indication, Dosing, SafetyWegovy is FDA-approved weekly (and now tablet) semaglutide for chronic weight management and certain heart-risk uses. See labeled doses, trials, and risks.
• Zepbound and Breastfeeding: Limited Milk DataZepbound's label reports low or undetectable tirzepatide in milk after a single 5 mg dose, with no infant-effect data. When to ask a clinician.
• Zepbound Explained: Indication, Dosing, and SafetyZepbound is FDA-approved weekly tirzepatide for chronic weight management and OSA in adults with obesity. Review labeled doses, SURMOUNT data, and risks.
• Zepbound Weekly Dosing Chart: Titration ScheduleZepbound starts at 2.5 mg weekly, then steps by 2.5 mg. See maintenance doses for weight and OSA, the 15 mg maximum, missed-dose rules, and labeled holds.

Frequently asked questions

Sources

1. [1] National Institute of Diabetes and Digestive and Kidney Diseases. Prescription medications to treat overweight and obesity.
2. [2] Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. [3] Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
4. [4] U.S. Food and Drug Administration. Medications containing semaglutide marketed for type 2 diabetes or weight loss.
5. [5] U.S. Food and Drug Administration. FDA intends to take action against unapproved GLP-1 drugs for weight loss (February 6, 2026).